Press Release
DemeRx Receives MHRA Approval for DMX-1002 (Ibogaine) to Commence Phase 1/2a Study as First Clinical Trial in Opioid Use Disorder in the UK
NEW YORK, March 10, 2021 /PRNewswire/ -- DemeRx IB, Inc. (DemeRx), an atai Life Sciences (atai) platform company focused on developing ibogaine for the treatment of opioid use disorder (OUD), today announced the company has approval from the UK Medicines and Healthcare products Regulatory Agency
Press Release
atai Life Sciences Announces the Closing of its $157 Million Series D Financing Round
NEW YORK, March 3, 2021 /PRNewswire/ --  atai Life Sciences  ("atai" or the "Company"), a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced the successful closing of its $157 million Series D
Press Release
Perception Neuroscience's PCN-101 (R-Ketamine) Demonstrates Tolerability in Phase 1 Single Ascending Dose Study
NEW YORK, Feb. 19, 2021 /PRNewswire/ -- Perception Neuroscience (Perception), an atai Life Sciences (atai) biopharmaceutical company focused on developing innovative therapies in neuropsychiatric diseases, today announced positive data from its first Phase 1 clinical study demonstrating the safety
Press Release
Joint feasibility assessment of Bionomics' BNC210 and EmpathBio's MDMA derivative EMP-01 treatment regimen for PTSD
ADELAIDE, Australia, Feb. 17, 2021 /PRNewswire/ --   Bionomics Limited (ASX: BNO,OTCQB: BNOEF , Germany: AU000000BNO5) ( Bionomics ) today announced that it has entered into a Memorandum of Understanding with EmpathBio Inc ( EmpathBio) , a wholly owned subsidiary of Germany-based CNS clinical
Press Release
atai Life Sciences to Collaborate with Massachusetts General Hospital to Accelerate Discovery of Mechanisms Underlying Therapeutic Effects of Psychedelic Agents
NEW YORK, Jan. 26, 2021 /PRNewswire/ -- atai Life Sciences  ("atai" or the "Company") , a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced it has entered into a collaboration with  Massachusetts General Hospital
Press Release
atai Life Sciences Acquires Majority Stake in Recognify Life Sciences to Develop Novel Treatment for Cognitive Impairment Associated with Schizophrenia
NEW YORK , Jan. 26, 2021 /PRNewswire/ -- atai Life Sciences  ("atai" or the "Company") , a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced it has entered into a collaboration with  Massachusetts General Hospital
Displaying 19 - 24 of 37